HealthEquity (NASDAQ:HQY) Stock Crosses Below Fifty Day Moving Average – Time to Sell?

HealthEquity, Inc. (NASDAQ:HQY – Get Free Report) crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $96.54 and traded as low as $94.37. HealthEquity shares last traded at $94.74, with a volume of 741,341 shares trading hands.

Analyst Upgrades and Downgrades

HQY has been the subject of several research analyst reports. BMO Capital Markets raised their price objective on HealthEquity from $105.00 to $125.00 and gave the company an “outperform” rating in a research note on Wednesday, October 21st. Deutsche Bank lifted their price objective on HealthEquity from $135.00 to $142.00 and gave the stock a “buy” rating in a research report on Monday, August 31st. Citigroup reissued a “market outperform” rating on shares of HealthEquity in a research report on Friday, August 28th. Barclays lifted their price target on HealthEquity from $110.00 to $115.00 and gave the company an “overweight” rating in a report on Friday, September 18th. Finally, BTIG Research reiterated a “buy” rating and issued a $115.00 target price on shares of HealthEquity in a report on Friday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $113.53.

View Our Latest Stock Analysis on HealthEquity

HealthEquity Trading Down 2.7%

The business has a 50 day simple moving average of $96.54 and a two-hundred day simple moving average of $90.35. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.47. The stock has a market cap of $7.84 billion, a price-to-earnings ratio of 34.20, a price-to-earnings-growth ratio of 1.50 and a beta of 0.22.

HealthEquity (NASDAQ:HQY – Get Free Report) last released its earnings results on Thursday, August 27th. The company reported $1.24 EPS for the quarter, beating the consensus estimate of $1.19 by $0.05. The company had revenue of $350.73 million during the quarter, compared to analysts’ expectations of $349.22 million. HealthEquity had a return on equity of 15.33% and a net margin of 17.36%. HealthEquity’s revenue for the quarter was up 95.5% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. As a group, equities analysts anticipate that HealthEquity, Inc. will post 3.94 EPS for the current year.

Insider Buying and Selling

In related news, Director Adrian Dillon sold 7,632 shares of the business’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $104.61, for a total value of $798,383.52. Following the completion of the sale, the director directly owned 62,395 shares of the company’s stock, valued at $6,527,140.95. The trade was a 10.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On HealthEquity

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new position in HealthEquity during the second quarter worth $1,018,621,000. Wasatch Advisors LP grew its position in shares of HealthEquity by 10.5% during the 2nd quarter. Wasatch Advisors LP now owns 7,960,735 shares of the company’s stock valued at $719,014,000 after buying an additional 757,801 shares during the last quarter. William Blair Investment Management LLC acquired a new stake in HealthEquity during the second quarter worth about $160,158,000. Dimensional Fund Advisors LP raised its stake in HealthEquity by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,627,039 shares of the company’s stock worth $135,957,000 after acquiring an additional 45,287 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in HealthEquity by 27.4% in the third quarter. Goldman Sachs Group Inc. now owns 1,283,552 shares of the company’s stock worth $113,543,000 after acquiring an additional 276,118 shares during the last quarter. 99.55% of the stock is currently owned by institutional investors.

HealthEquity Company Profile

(Get Free Report)

HealthEquity, Inc. provides technology and services for health savings accounts (HSAs) and other consumer-directed benefits. Its platform supports employers, health plans, benefits advisers and individuals in managing health-related accounts and benefits. Alongside HSAs, the company administers flexible spending accounts, health reimbursement arrangements, commuter benefits and other workplace benefit programs. Its services include account administration, payment tools, customer support and investment options for eligible HSA funds.

See Also

Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.